This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vesselle, H. Articles by Wood, D. E. Search for Related Content PubMed PubMed Citation Articles by Vesselle, H. Articles by Wood, D. E. Related Collections Related Article

Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role

Authors' Affiliations: Departments of ¹ Radiology, ² Pathology, ³ Epidemiology, and ⁴ Surgery (Thoracic), University of Washington, Seattle, Washington

Requests for reprints: Hubert Vesselle, Department of Radiology, University of Washington, Seattle, Washington. Phone: 206-543-3320; Fax: 206-543-6317; E-mail: vesselle{at}u.washington.edu.

Purpose: This prospective study evaluated the prognostic significance of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake in primary non-small cell lung cancer (NSCLC) at positron emission tomography, in a carefully staged population, while correcting for partial volume effects.

Experimental Design: Two hundred eight potentially resectable NSCLC patients were referred for FDG positron emission tomography staging after thoracic computed tomography. Each tumor stage was confirmed surgically, or for some stage IV tumors by additional imaging. The tumor maximum pixel-standardized uptake value (maxSUV) and the maxSUV partial volume corrected for lesion size (PVCmaxSUV) were compared with overall survival and disease-free survival using Cox proportional hazards regression.

Results: Stage distribution: stage I, 36%; stage II, 15%; stage III, 30%; stage IV, 19%. Patients were followed for a median of 33.6 months, with 90 deaths from NSCLC (median survival for all stages, 43.3 months). With respect to overall survival, the most significant cutoff value for both maxSUV and PVCmaxSUV was 7. MaxSUV 7 was significantly associated with an increased risk of death from NSCLC in univariable analysis, whereas PVCmaxSUV 7 was only marginally associated. However, in multivariable analyses, neither maxSUV 7 nor PVCmaxSUV 7 provided significant additional prognostic information over stage, tumor size, and age. In the 103 patients who underwent surgical resection only, surgical stage, but not maxSUV or PVCmaxSUV, was univariably associated with survival or recurrence. SUV definitions based on lean body mass, body surface area, and plasma glucose correction yielded identical results.

Conclusions: As expected, tumor stage is prognostic in NSCLC. However, tumor FDG uptake does not provide additional prognostic information. This prospective study contradicts prior reports.

Related Article

Prognostic Significance of Fluorodeoxyglucose Uptake in Non–Small Cell Lung Cancer. A Blurry Picture?

Wolfgang A. Weber, Johannes Czernin, and Michael E. Phelps
Clin. Cancer Res. 2007 13: 3105-3106. [Full Text] [PDF]

This article has been cited by other articles:

				Y. J. Lee, A. Cho, B. C. Cho, M. Yun, S. K. Kim, J. Chang, J. W. Moon, I. K. Park, H. J. Choi, and J.-H. Kim High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2426 - 2432. [Abstract] [Full Text] [PDF]

				N. Al-Sarraf, K. Gately, J. Lucey, R. Aziz, K. Doddakula, L. Wilson, E. McGovern, and V. Young Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 892 - 897. [Abstract] [Full Text] [PDF]

				J. K. Hoang, L. F. Hoagland, R. E. Coleman, A. D. Coan, J. E. Herndon II, and E. F. Patz Jr Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non-Small-Cell Lung Carcinoma J. Clin. Oncol., March 20, 2008; 26(9): 1459 - 1464. [Abstract] [Full Text] [PDF]

				Q. Feng, S. E. Hawes, J. E. Stern, L. Wiens, H. Lu, Z. M. Dong, C. D. Jordan, N. B. Kiviat, and H. Vesselle DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 645 - 654. [Abstract] [Full Text] [PDF]

				W. A. Weber, J. Czernin, and M. E. Phelps Prognostic Significance of Fluorodeoxyglucose Uptake in Non-Small Cell Lung Cancer. A Blurry Picture? Clin. Cancer Res., June 1, 2007; 13(11): 3105 - 3106. [Full Text] [PDF]